

CNS Research, Inc
16 Haliburton Road
East Providence, RI 02916

Phone: 1-800-707-6013
Fax: 1-800-847-4332
Email: fred@cns-research.com

Fred Griffith, MD

EDUCATION

Undergraduate	Yale University New Haven, CT Philosophy/Psychology BA 1972
Medical School	University of Rochester Rochester, NY 1974 to 1978 MD 1978

POSTGRADUATE TRAINING

Residency	Rhode Island Hospital Providence, RI Internal Medicine 1978 to 1981
	New England Medical Center Boston, MA Neurology 1981 to 1984

RESEARCH AFFILIATIONS:

CNS Research, Inc.	450 Veterans' Memorial Parkway #11 East Providence, RI 02914
CNS Research, Inc	360 Kingstown Rd, Unit 102 Narragansett, RI 02882
CNS Research, Inc.	16 Haliburton Road East Providence, RI 02916

PUBLICATIONS

Baldessarini, R., T. Amatruda, F. Griffith, and S. Gerson
“Differential Effects of Serotonin on Turning and Stereotypy Induced by Apomorphine,”
Brain Research 93: 158-163, 1975.

Baldessarini, R., and F. Griffith, “Acute Increases by p-Chlorophenylalanine of Apomorphine-Induced Stereotyped Behavior in the Rat,” *Psychopharmacologia* 48:91-95, 1976.

RESEARCH EXPERIENCE

A Randomized, Double Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain.

Phase III, “A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine.”

A Double-Blind, Randomized, Multicenter, Parallel Group Study to Establish Dose-Response, Safety and Efficacy of Zonisamide (Zonegran™) as Monotherapy in Patients with Newly Diagnosed Epilepsy.

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG®) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine.

A Prospective, 26-Week, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy and Safety of Exelon (rivastigmine tartrate) 3-12 mg/day in Patients with Mild to Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept (donepezil) Treatment.

BiogenIdec: 109MS301: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis

BiogenIdec: 109MS303: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis.